RankAlpha logo
Back to Rankings

CRL

Charles River Laboratories InternationalA
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is that CRL has already reaffirmed 2026 guidance, says DSA demand is tracking expectations, and has a clearer portfolio after divestitures, with an added AI/NAM positioning angle from TuneLab [#SEC-8K-2026-05-07] [#IR-2026-06-18].
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Non-GAAP operating margin fell to 16.3% in Q1 because of higher DSA study-related direct costs, unfavorable RMS mix, and higher stock-based compensation [#SEC-8K-2026-05-07].
Momentum
90
Value
62
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $220.00 · Bull $255.00 · Bear $185.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-01 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $237.79
Why
Momentum90 · Δ7d +8.9
Value62 · Δ7d +0.1
Sentiment44 · Δ7d +0.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
90
26% active weight
Current posture
7d trendImproving
Δ7d
+8.9
Δ21d
+8.8
Value
62
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.2
Sentiment
44
34% active weight
Current posture
7d trendFlat
Δ7d
+0.7
Δ21d
+5.5
Why this grade

Composite grade A. Momentum 89.9 / Value 61.5 / Sentiment 44.1

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$10.81B
Beta
1.63
Shares Out
48.17M
P/E (TTM) · Derived
-77.0
P/S (TTM)
2.55
P/FCF (TTM)
18.86
Rev YoY
+1.2%
EPS YoY
-160.5%
Gross Margin
+31.3%
Op Margin
+3.5%
Net Debt
$2.42B
Current Ratio
1.36
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology